<DOC>
	<DOCNO>NCT00043095</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine BMS-247550 gemcitabine treat patient advance solid tumor .</brief_summary>
	<brief_title>BMS-247550 Gemcitabine Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , dose-limiting toxicity , safety BMS-247550 combined gemcitabine patient advance solid tumor . - Determine plasma pharmacokinetics regimen patient population . - Assess , preliminarily , antitumor activity regimen patient population . OUTLINE : This dose-escalation study BMS-247550 . Patients receive gemcitabine IV 90 minute day 1 8 follow BMS-247550 IV 3 hour day 8 . The order chemotherapy drug administration day 8 reversed second course . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos BMS-247550 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Once MTD determine , 9 patient total treated MTD . PROJECTED ACCRUAL : A maximum 40 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonhematological cancer unresponsive currently available therapy know effective treatment Clinical radiological evidence disease require No active brain metastasis , include evidence cerebral edema ( CT scan MRI ) , progression prior image study , requirement steroid , clinical symptom PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic Bilirubin great 1.5 mg/dL ALT AST great 2.5 time upper limit normal ( ULN ) 93 U/L Renal Creatinine great 1.5 time ULN 2.0 mg/dL Other No document hypersensitivity reaction prior paclitaxel therapy contain Cremophor EL No grade 2 great preexist peripheral neuropathy No serious uncontrolled medical disorder active infection would preclude study therapy No dementia alter mental status would preclude informed consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior immunotherapy Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , doxorubicin HCl liposome ) Prior taxanes allow Prior adjuvant neoadjuvant chemotherapy allow No 2 prior chemotherapy regimen metastatic set No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent hormonal therapy except hormonereplacement therapy Concurrent medication maintain castrate status progressive hormonerefractory prostate cancer allow Radiotherapy At least 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery Not specify Other At least 4 week since prior investigational agent No concurrent experimental anticancer medication No concurrent alternative therapy ( e.g. , highdose vitamin herbal medicine ) No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2005</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>